CARDIAC PACEMAKER MARKET ANALYSIS

Name: Cardiac Pacemaker Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Cardiac Pacemaker Market, By Product Type (Single-chamber Pacemaker, Dual-chamber Pacemaker, Biventricular Pacemaker), By Implantability (Implantable Pacemakers and External Pacemakers), By End User (Hospitals, Cardiac Clinics, Ambulatory Surgical Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In July 2023, Abbott, a medical device company, announced that the U.S. Food and Drug Administration (FDA) had approved the AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. Leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow or abnormal heart rhythms.
In July 2022, Abbott, a medical device company, announced that its investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial
In June 2021, Medtronic, a medical device company, announced the launch of Micra A, a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to Atrioventricular (AV) block patients through a minimally invasive approach